116 related articles for article (PubMed ID: 30308940)
1. Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment.
McCann HD; Johnson CE; Errington RJ; Davies DM; Dunlop EA; Tee AR
Cancers (Basel); 2018 Oct; 10(10):. PubMed ID: 30308940
[TBL] [Abstract][Full Text] [Related]
2. Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death.
Johnson CE; Dunlop EA; Seifan S; McCann HD; Hay T; Parfitt GJ; Jones AT; Giles PJ; Shen MH; Sampson JR; Errington RJ; Davies DM; Tee AR
Oncogene; 2018 Nov; 37(45):5913-5925. PubMed ID: 29980790
[TBL] [Abstract][Full Text] [Related]
3. Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells.
Dunlop EA; Johnson CE; Wiltshire M; Errington RJ; Tee AR
Oncotarget; 2017 Jul; 8(30):48711-48724. PubMed ID: 28415776
[TBL] [Abstract][Full Text] [Related]
4. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
McEneaney LJ; Tee AR
Adv Genet; 2019; 103():91-118. PubMed ID: 30904097
[TBL] [Abstract][Full Text] [Related]
5. Vps34-mediated macropinocytosis in Tuberous Sclerosis Complex 2-deficient cells supports tumorigenesis.
Filippakis H; Belaid A; Siroky B; Wu C; Alesi N; Hougard T; Nijmeh J; Lam HC; Henske EP
Sci Rep; 2018 Sep; 8(1):14161. PubMed ID: 30242175
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells.
Krishnamoorthy J; Tenkerian C; Gupta J; Ghaddar N; Wang S; Darini C; Staschke KA; Ghosh A; Gandin V; Topisirovic I; Kristof AS; Hatzoglou M; Simos G; Koromilas AE
Cell Death Dis; 2018 Feb; 9(3):254. PubMed ID: 29449538
[TBL] [Abstract][Full Text] [Related]
7. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
[TBL] [Abstract][Full Text] [Related]
8. Drug Inhibition of Redox Factor-1 Restores Hypoxia-Driven Changes in Tuberous Sclerosis Complex 2 Deficient Cells.
Champion JD; Dodd KM; Lam HC; Alzahrani MAM; Seifan S; Rad E; Scourfield DO; Fishel ML; Calver BL; Ager A; Henske EP; Davies DM; Kelley MR; Tee AR
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551683
[TBL] [Abstract][Full Text] [Related]
9. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
[TBL] [Abstract][Full Text] [Related]
10. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
[TBL] [Abstract][Full Text] [Related]
11. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2
Jones AT; Narov K; Yang J; Sampson JR; Shen MH
Neoplasia; 2019 Feb; 21(2):230-238. PubMed ID: 30622053
[TBL] [Abstract][Full Text] [Related]
13. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
14. Abnormal glycogen storage in tuberous sclerosis complex caused by impairment of mTORC1-dependent and -independent signaling pathways.
Pal R; Xiong Y; Sardiello M
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2977-2986. PubMed ID: 30728291
[TBL] [Abstract][Full Text] [Related]
15. Differential IKK/NF-κB Activity Is Mediated by TSC2 through mTORC1 in PTEN-Null Prostate Cancer and Tuberous Sclerosis Complex Tumor Cells.
Gao Y; Gartenhaus RB; Lapidus RG; Hussain A; Zhang Y; Wang X; Dan HC
Mol Cancer Res; 2015 Dec; 13(12):1602-14. PubMed ID: 26374334
[TBL] [Abstract][Full Text] [Related]
16. Hyperactivated mTORC1 downregulation of FOXO3a/PDGFRα/AKT cascade restrains tuberous sclerosis complex-associated tumor development.
Wang L; Ni Z; Liu Y; Ji S; Jin F; Jiang K; Ma J; Ren C; Zhang H; Hu Z; Zha X
Oncotarget; 2017 Aug; 8(33):54858-54872. PubMed ID: 28903387
[TBL] [Abstract][Full Text] [Related]
17. mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.
Li J; Shin S; Sun Y; Yoon SO; Li C; Zhang E; Yu J; Zhang J; Blenis J
Cancer Res; 2016 Aug; 76(16):4816-27. PubMed ID: 27197195
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R.
Filippakis H; Alesi N; Ogorek B; Nijmeh J; Khabibullin D; Gutierrez C; Valvezan AJ; Cunningham J; Priolo C; Henske EP
Oncotarget; 2017 Jun; 8(24):38099-38112. PubMed ID: 28498820
[TBL] [Abstract][Full Text] [Related]
19. mTOR Hyperactivation by Ablation of Tuberous Sclerosis Complex 2 in the Mouse Heart Induces Cardiac Dysfunction with the Increased Number of Small Mitochondria Mediated through the Down-Regulation of Autophagy.
Taneike M; Nishida K; Omiya S; Zarrinpashneh E; Misaka T; Kitazume-Taneike R; Austin R; Takaoka M; Yamaguchi O; Gambello MJ; Shah AM; Otsu K
PLoS One; 2016; 11(3):e0152628. PubMed ID: 27023784
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
